Does UnitedHealthcare Cover Alprostadil (Caverject/MUSE)?

What Is Alprostadil and Why Is It Prescribed?

Alprostadil is a synthetic prostaglandin E1 that relaxes smooth muscle and dilates penile arterial blood vessels, producing an erection sufficient for intercourse. Two delivery forms are commercially available in the United States: Caverject (intracavernosal injection, 10 mcg and 20 mcg doses) and MUSE (medicated urethral system for erection, a 125 mcg to 1 to 000 mcg suppository). Both are prescription-only and FDA-approved specifically for erectile dysfunction that has not responded adequately to less invasive treatments. [1]

The 1996 Linet et al. trial published in the New England Journal of Medicine (N=296) established alprostadil's clinical standing. In that study, 94.8% of alprostadil injection attempts produced erections rated satisfactory for intercourse versus 13.5% with placebo injections (P<0.001). [2] That efficacy data has anchored alprostadil's position in erectile dysfunction treatment algorithms for nearly three decades.

The American Urological Association 2018 guideline on erectile dysfunction states that "intracavernosal injection therapy is highly effective and should be offered to patients who fail or are intolerant of oral agents." [3] That guideline framing matters for insurance purposes because it directly supports the medical necessity language required by UnitedHealthcare when you submit a prior authorization.

Alprostadil is not approved for, and UnitedHealthcare will not cover it for, weight loss or any metabolic indication. Men who receive alprostadil do so exclusively for documented erectile dysfunction.

How UnitedHealthcare Classifies Alprostadil on Its Formulary

On most UnitedHealthcare commercial PPO and HMO plans, alprostadil (both Caverject and MUSE) sits at Tier 3. Tier 3 is typically designated for preferred brand-name drugs. [4] That tier placement means your cost-sharing is higher than a generic or preferred brand, but the drug is covered rather than excluded outright.

A few important caveats apply. Formulary placement varies by plan year, employer group contract, and state. Medicare Advantage plans follow Part D formulary rules, and some UHC Medicare plans place Caverject on Tier 4 or restrict it further. Medicaid managed care plans administered by UHC in some states may exclude the drug entirely or require additional criteria.

The cleanest way to confirm your specific plan's tier is to log into your UHC member portal at myuhc.com, enter the drug name under "Prescription Benefits," and select your preferred pharmacy. You can also call the Member Services number on your insurance card and ask the representative specifically for the formulary tier and any attached coverage conditions. Get the representative's name and the call reference number; document both before you hang up.

Copay amounts for Tier 3 vary widely. A 30-day supply of Caverject can carry a copay anywhere from $60 to $180 depending on the employer group contract. [5] Generic alprostadil injection is available from compounding pharmacies at lower cost, but most UHC plans only cover FDA-approved commercial formulations, not compounded versions, unless the prescribing physician documents a clinical reason the commercial product cannot be used.

Prior Authorization Criteria for Alprostadil on UHC Plans

Prior authorization is required on virtually every UHC commercial plan that covers alprostadil. The difficulty rating for this PA is moderate, meaning approval is achievable with adequate documentation but rarely automatic.

UHC's standard criteria for alprostadil PA approval include: a confirmed diagnosis of erectile dysfunction coded with ICD-10 N52.xx; documentation that at least one oral phosphodiesterase-5 (PDE5) inhibitor (sildenafil, tadalafil, vardenafil, or avanafil) was tried at an adequate dose for a sufficient trial period and either failed to produce adequate erections or caused intolerable side effects; and a statement of medical necessity from a licensed prescribing physician, typically a urologist or primary care provider who manages men's health. [6]

Some plans also require that the prescribing physician document why the injectable or suppository form is appropriate, particularly if the patient has cardiovascular risk factors. The FDA label for Caverject carries warnings about priapism (sustained erection lasting more than four hours) and penile fibrosis with repeated injection, so UHC reviewers may request confirmation that the prescriber discussed these risks with the patient. [1]

If a PDE5 inhibitor is contraindicated because the patient takes nitrate medications for angina, UHC generally accepts that contraindication as an alternative pathway to PA approval without requiring a failed PDE5 trial first. Documented nitrate use in the medical record is usually sufficient.

The HealthRX PA Readiness Checklist for alprostadil UHC submissions:

1. ICD-10 code N52.xx on all claim and PA documents.
2. Name, dose, duration, and outcome of at least one PDE5 inhibitor trial. Sildenafil 50 mg or 100 mg for at least four separate attempts is a commonly accepted threshold.
3. Prescribing physician's attestation that alprostadil is medically necessary given the patient's history.
4. If nitrate contraindication applies: copy of current medication list showing the nitrate and a brief note explaining why PDE5 use is unsafe.
5. Office note dated within the past 12 months documenting active erectile dysfunction.

Step Therapy Requirements Before Alprostadil Coverage

Most UHC commercial plans impose step therapy, requiring trial of a lower-tier oral agent before covering alprostadil. The standard step is one oral PDE5 inhibitor. That step is generally considered met after a documented trial of sildenafil 50 mg or 100 mg or tadalafil 10 mg or 20 mg on at least three to four separate occasions without adequate response. [7]

Step therapy requirements for erectile dysfunction drugs have faced legislative scrutiny. As of 2023, 34 states have enacted step therapy reform laws requiring insurers to grant exceptions when step therapy is clinically inappropriate, when the required drug is contraindicated, or when the patient already failed the required drug. [8] If your state has such a law and UHC administers a state-regulated plan (not a self-funded ERISA plan), you have a statutory right to request a step therapy exception rather than repeating a failed trial.

Self-funded employer plans governed by ERISA are exempt from most state step therapy laws, so that exception pathway may not apply if your employer is self-insured. Ask UHC Member Services whether your plan is fully insured or self-funded. That single answer determines which appeal rules govern your case.

Documented intolerance to PDE5 inhibitors, including flushing, visual disturbances, severe headache, or hypotension, can substitute for a failed efficacy trial. The key is that the intolerance is recorded in the clinical chart and referenced explicitly in the PA request letter.

What Alprostadil Costs Without Insurance Approval

Without insurance coverage, alprostadil carries a list price of approximately $600 per month for either the Caverject or MUSE formulation. [9] That figure reflects single-use vials or suppositories at typical prescribing quantities. Patients using Caverject at a starting dose of 2.5 mcg titrating to 10 to 20 mcg typically inject two to three times per week, which drives monthly unit counts higher and can push total cost above $600 at some pharmacies.

GoodRx coupons reduce the out-of-pocket price at certain retail pharmacies. Caverject 20 mcg (6 vials) lists near $450 to $520 with GoodRx at major chains as of mid-2025, though prices vary by zip code. MUSE 500 mcg (10 suppositories) runs roughly $380 to $430 with discount codes at similar chains.

The Pfizer Caverject patient savings program provides eligible commercially insured patients a copay reduction card that may reduce cost-sharing to as low as $0 to $30 per fill. This card is not valid for patients covered by Medicare, Medicaid, TRICARE, or any other federal or state government program. [10] Eligibility and terms change, so patients should verify current program terms directly at the manufacturer website or by calling the program hotline on the savings card packaging.

Compounded alprostadil injection from a 503A specialty compounding pharmacy can cost $80 to $150 per month and may be appropriate when the patient cannot tolerate the commercial formulation or needs a non-standard concentration. Most UHC plans will not reimburse compounded alprostadil, so this path is generally cash-pay.

How to Get UHC to Approve Alprostadil: The PA Submission Process

The prescribing physician's office initiates the PA request, not the patient. However, patients who understand the process move it faster. Here is the typical sequence:

Your physician submits a PA request via the UHC provider portal or fax. UHC has 15 calendar days to issue a standard decision and 72 hours for an urgent decision under federal utilization review standards. [11] The 72-hour pathway applies when the treating physician certifies that a delay would seriously jeopardize health.

UHC's medical reviewers will compare the submitted clinical information against UHC's coverage determination policy for erectile dysfunction drugs. That policy document is publicly accessible through the UHC Coverage Determination Guidelines library at myuhc.com. Reading it before submission lets your physician tailor the clinical letter to match UHC's exact language.

If the initial PA is denied, the denial letter must state the specific clinical reason for denial and the exact criteria not met. Federal rules under the ACA require this level of specificity. [12] A vague denial that cites only "not medically necessary" without specifying which criterion failed is itself grounds for an appeal argument.

Appealing a UHC Denial of Alprostadil

Two internal appeal levels exist before the case moves to an external independent review organization. The first internal appeal must be filed within 180 days of the denial notice on most commercial plans. UHC must respond to a standard first-level appeal within 30 calendar days for prospective reviews and within 60 days for retrospective reviews. [13]

The first-level appeal letter should directly address each stated denial reason. If UHC says the patient did not meet step therapy criteria, attach pharmacy records or physician notes proving the PDE5 inhibitor was tried. If UHC says the diagnosis is insufficient, attach the full office note with the ICD-10 code. Specificity wins appeals. Generic letters that repeat the original PA text rarely succeed.

The second internal appeal, sometimes called the final internal review, must receive a decision within the same 30-day timeframe for prospective cases. If both internal levels fail, you have the right to external review by an independent review organization (IRO) under ACA Section 2719 rules. The IRO's decision is binding on UHC. [14] IRO reviewers are board-certified clinicians who have no financial relationship with the insurer, which makes this pathway genuinely useful for cases with solid clinical documentation.

Key documents to gather before filing any appeal:

• The complete denial letter with the specific denial code and reason.
• A copy of UHC's own coverage determination guideline for erectile dysfunction (download it from their provider portal).
• Peer-reviewed literature supporting alprostadil's use in your specific clinical situation. The Linet 1996 NEJM trial (N=296 to 94.8% satisfactory erection rate with alprostadil vs. 13.5% with placebo) is directly citable here. [2]
• A letter of medical necessity from the prescribing physician that quotes the AUA guideline language directly. [3]
• Any relevant state step therapy exception statute if your plan is fully insured.

If the IRO also denies the claim, the final option is filing a complaint with your state's Department of Insurance (for fully insured plans) or with the U.S. Department of Labor Employee Benefits Security Administration (for self-funded ERISA plans). [15]

UHC Medicare Advantage and Medicaid Coverage for Alprostadil

Medicare Part D does cover alprostadil in principle, but congressional statute 42 U.S.C. 1395w-102(e)(2)(A) historically excluded drugs used "for the treatment of sexual or erectile dysfunction" from the standard Part D benefit unless the drug is also indicated for another covered condition. [16] Some Medicare Advantage plans with enhanced supplemental benefits have added erectile dysfunction drugs to their formulary, but this is plan-specific and far from universal.

UHC Medicare Advantage members should request the plan's Evidence of Coverage document and search specifically for "erectile dysfunction" in the drug benefit section. If the drug appears with a coverage condition, the PA criteria for Medicare plans may differ from commercial criteria and are regulated under Centers for Medicare and Medicaid Services (CMS) rules rather than state insurance law.

UHC-administered Medicaid plans vary by state. Several states exclude erectile dysfunction medications from Medicaid coverage by state plan design. Others cover alprostadil with PA for documented medical necessity. A call to UHC Member Services and a separate call to your state Medicaid office together confirm coverage faster than relying on either source alone.

Clinical Context: Why Physicians Prescribe Alprostadil Over Oral Agents

Alprostadil is not a first-line drug. Oral PDE5 inhibitors (sildenafil, tadalafil, vardenafil, avanafil) are the standard first step in erectile dysfunction treatment because they are effective, well-tolerated, and easy to take. The Massachusetts Male Aging Study found that erectile dysfunction affects approximately 52% of men between ages 40 and 70, with complete erectile dysfunction affecting 10% of that group. [17] Most of those men respond to oral therapy.

Men for whom alprostadil is prescribed fall into a smaller, harder-to-treat group. This includes men with diabetes-related neuropathy and vasculopathy, men who have undergone radical prostatectomy for prostate cancer with nerve damage, men on nitrate medications for whom PDE5 inhibitors are contraindicated, and men with documented penile vascular insufficiency on Doppler ultrasound. [18] In radical prostatectomy patients specifically, studies report that PDE5 inhibitor efficacy drops to 35 to 40%, while intracavernosal alprostadil produces clinically adequate erections in 70 to 80% of the same population. [19]

The European Association of Urology 2023 guidelines on sexual and reproductive health note that intracavernosal injection therapy with alprostadil is a recommended second-line treatment after oral PDE5 inhibitors, with evidence grade A for efficacy in PDE5 non-responders. [20] UHC reviewers trained in evidence-based medicine respond to that grade-A designation; including the EAU citation in an appeal letter adds weight.

Alprostadil Dosing and Administration: What UHC Reviewers Expect to See

UHC's PA reviewers look for a prescribing plan that matches FDA-label dosing. For Caverject intracavernosal injection, the FDA-approved starting dose is 2.5 mcg for men with neurogenic erectile dysfunction and 5 mcg for vasculogenic or psychogenic etiologies. Dose titration occurs in the physician's office in 5 mcg to 10 mcg increments, with a maximum single dose of 40 mcg. [1] The prescribing plan should document titration as an in-office procedure with the physician present for the first injection. That detail signals appropriate use and reduces the insurer's concern about priapism risk.

For MUSE, dosing ranges from 125 mcg to 1 to 000 mcg administered as a urethral suppository 5 to 10 minutes before anticipated intercourse. Response rates for MUSE are lower than for intracavernosal injection; the key MUSE trial (N=1,511) reported 64.9% of patients achieving at least one successful intercourse episode in-clinic versus 18.6% with placebo. [21] That on-demand success rate drops in real-world use, with about 40 to 50% of men continuing MUSE at 6 months, partly because some men find the urethral administration technique uncomfortable.

The prescribing physician's choice between Caverject and MUSE often comes down to patient preference for administration route. Both are covered under the same UHC prior authorization policy.

Special Populations and Additional Documentation UHC May Request

Men with diabetes. Diabetic erectile dysfunction often involves both neuropathic and vasculogenic components. UHC may request a recent HbA1c result and a note confirming the treating endocrinologist or primary care physician is managing glycemic control. Uncontrolled diabetes (HbA1c above 9%) may prompt additional scrutiny. [22]

Men post-radical prostatectomy. Include the operative report or a urology note confirming nerve-sparing or non-nerve-sparing surgery. The type of prostatectomy directly predicts PDE5 inhibitor response and supports medical necessity for alprostadil when PDE5 therapy is inadequate. [19]

Men with cardiovascular disease. Alprostadil itself does not carry the same hemodynamic risks as PDE5 inhibitors when combined with nitrates, because its mechanism bypasses the nitric oxide pathway. [1] A brief note from the cardiologist confirming the patient is stable enough for the physical activity involved in sexual intercourse (generally equivalent to two flights of stairs at a brisk pace) can preempt a UHC request for additional cardiac clearance. [23]

Psychological erectile dysfunction. If the etiology is primarily psychogenic, UHC may ask why a PDE5 inhibitor is insufficient before covering alprostadil. Documentation of PDE5 failure on a minimum of three to four attempts at the maximum tolerated dose, combined with a note from a mental health provider confirming concurrent psychological treatment, strengthens the case.

State-Specific Rules That Affect UHC Coverage

Several states have enacted laws that expand erectile dysfunction drug coverage or limit insurer discretion. California SB 1145 (2022) requires fully insured health plans to cover FDA-approved erectile dysfunction treatments with no more restrictive limits than comparable drugs for other conditions. [24] Texas and New York have similar parity provisions under their respective insurance codes.

If you live in one of these states and hold a fully insured UHC plan, a denial that is inconsistent with state parity law can be appealed to the state Department of Insurance simultaneously with the UHC internal appeal. Filing both simultaneously creates an external accountability track that sometimes accelerates UHC's internal reconsideration.

ERISA self-funded plans are preempted from state insurance law, so these state protections do not apply to that plan type. Confirming your plan type before selecting an appeal strategy saves weeks.